Coroner Rules Out Effects of Flu Drug in Ferrari Crash – 02Nov2012
Coroner rules out effects of flu drug in Ferrari crash – 02Nov2012 – A coroner’s inquest into the death of Ferrari driver Ma Chi has ruled out the possibility that the flu drugs found in his body was a factor in the crash. The court heard on Wednesday that traces of chlorpheniramine, an antihistaminic drug used to treat flu or allergy, was found in Ma’s urine sample. However, State Coroner Imran Abdul Hamid on Friday rejected the possibility of the medication having any effect on Ma, as the drug was “in the process of being excreted out” from Ma’s body. He noted that Ma, who was travelling at 178 kilometres per hour before the crash, had “created a situation where it was extremely difficult to react to road conditions”. Mr Imran revealed these findings at a coroner’s inquiry into the high-profile accident on 12 May 2012, which left three people dead. He concluded that Ma, a Chinese national, died from severe head injuries when his car crashed into the side of Mr Cheng Teck Hock’s taxi. According to an autopsy report, both 52-year-old Cheng and his passenger, 41-year-old Japanese national Ito Shigemi, died from multiple injuries. The inquiry heard that Ma, who had previously owned a BMW 3 Series car, was out “practising” his driving before picking up his friend Ms Wu Wei Wei from a nightclub in Clarke Quay. The subsequent crash occurred at the junction of Rochor Road and Victoria Street. The accident was recorded by various CCTVs and an in-vehicle camera of Ma’s car, which Mr Imran noted was a “keypiece” as it gave “relatively good driver’s …
AcelRx pain treatment as effective as standard care in trial
Filed under: drug treatment news 2013
(Reuters) – AcelRx Pharmaceuticals Inc said its drug-device combination for post-operative pain was at least as effective as the standard of care, suggesting it has the potential to replace the current treatment. AcelRx plans to file for marketing …
Read more on Reuters
PropThink: Endocyte – A Safe Bet for 2013
Filed under: drug treatment news 2013
Vintafolide is a small molecule drug conjugate that targets the folate receptor (preferentially expressed on numerous cancers) to deliver a highly potent chemotherapeutic agent (DAVLBH in the case of vintafolide) and is partnered with Merck (NYSE:MRK …
Read more on Reuters